|
Mar 5
|
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
|
|
Mar 5
|
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
|
|
Mar 4
|
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
|
|
Mar 4
|
1 Wall Street Analyst Thinks Viking Therapeutics Stock Is Going to $116. Is It a Buy Around $81?
|
|
Jan 10
|
The 3 Best Biotech Stocks to Buy in January 2024
|
|
Dec 8
|
Why Viking Therapeutics Was Crushing It This Week
|
|
Dec 3
|
Obesity Drugs Have Multi-Billion-Dollar Market Potential, Says Oppenheimer — Here Are 2 Stocks to Take Advantage
|
|
Nov 28
|
Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company
|
|
Nov 13
|
Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023
|
|
Nov 4
|
1 Under-the-Radar Stock That Could Triple By 2030
|
|
Sep 7
|
Viking Therapeutics to Participate at Upcoming Investor Conferences
|
|
Sep 6
|
Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
|
|
Aug 9
|
Ligand (LGND) Up 4% on Raised '23 EPS, Beats on Q2 Earnings
|
|
Aug 8
|
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today
|
|
Jun 27
|
Why Viking Therapeutics Is Plunging Today
|
|
Jun 27
|
Why Viking Therapeutics Stock Is Crashing Today
|
|
Jun 22
|
3 Biotech Stocks to Buy as Companies Ink Major Deals
|